FIELD: pharmacology.
SUBSTANCE: invention provides a pharmaceutical combination influencing central nervous system function, which contains (i) at least one compound influencing central nervous system function; (ii) at least one compound beneficially affecting central nervous system, and compound assisting first compound to cross blood-brain barrier, namely an agent for endonasal administration manifesting reflex, preferably neuro- and vasoactive action on nasal mucosa structures and receptors, basically receptors of vomeronasal organ and trigeminal nerve systems; (iii) active oxygen forms selected from hydrogen superoxide, hydrogen peroxide, NO-, and CO-active compounds; and (iv) pharmacological stabilizer.
EFFECT: lowered doses and reduced adverse effects.
22 cl, 2 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS, PHARMACEUTICAL COMPOSITIONS AND PRODUCTS FOR THERAPEUTIC CELL INTRODUCTION INTO ANIMAL'S CENTRAL NERVOUS SYSTEM | 2008 |
|
RU2468818C2 |
METHOD FOR TREATING ISCHEMIA AND CEREBRAL LESION WITH A NEUROPROTECTOR PREPARATION | 1996 |
|
RU2194527C2 |
DRUG PREPARATION FOR PARKINSON DISEASE | 2014 |
|
RU2545734C1 |
PHARMACEUTICAL COMPOSITION "MICEREBROPHON" HAVING NOOTROPIC ACTIVITY | 2010 |
|
RU2441657C1 |
DERIVATIVE OF PYRROLIDINE ACETAMIDE OR ITS COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | 2000 |
|
RU2261093C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING SKIN ITCHING | 2012 |
|
RU2543326C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING OR RELIEVING MOVEMENT DISORDERS AND ITS APPLICATION | 2011 |
|
RU2611376C2 |
PHARMACEUTICAL COMPOSITION FOR RECOVERY FUNCTION OF SYMPATHETIC-ADRENAL SYSTEM, METHOD OF EVALUATION OF INDIVIDUAL EFFECTIVENESS OF THIS COMPOSITION FOR PATIENT THERAPY | 1999 |
|
RU2157196C1 |
APPLICATION OF N-DISMETILKLOSAPINE FOR HUMAN NEUROPSYCHIATRIC DISEASES TREATMENT | 2004 |
|
RU2336879C2 |
BLOOD BRAIN BARRIER SHUTTLE | 2013 |
|
RU2663120C2 |
Authors
Dates
2005-06-10—Published
2004-04-30—Filed